Trial site
REUMAMED POPRAD, s.r.o.
Poprad, 05801, SlovakiaEU-13 widening countryNot linked to an institution yet
- 7running trials
- 1closed trial
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 22 trials
- Phase 41 trial
- Status
- Active, not recruiting4 trials
- Not yet recruiting2 trials
- Completed1 trial
- Recruiting1 trial
- Lead sponsor
- AbbVie2 trials
- Janssen Research & Development, LLC2 trials
- MoonLake Immunotherapeutics AG2 trials
- Novartis Pharmaceuticals2 trials
Running trials
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· Phase 3· Novartis Pharmaceuticals· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446· Phase 2· AbbVie· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· Phase 4· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308· Phase 3· AbbVie· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error